mTOR Signaling: A Key Player in X-Linked Alport Syndrome Disease Progression (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0125; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Because rapamycin can have undesirable side effects in humans, we repeated the experiment using rapamycin and three alternative interventions (meclizine, alpelisib, and fisetin) starting at 4-weeks of age...Results Glomerular filtration rate, a measure of kidney function, showed no significant treatment effects, while albumin-to-creatinine ratio, a measure of kidney damage, demonstrated that rapamycin, meclizine, and fisetin significantly reduced kidney damage. Conclusion Together, these findings show that targeting specific components of the mTOR pathway can reduce kidney damage in XLAS mice and highlight mTOR pathway modulation as a promising therapeutic strategy for Alport-related kidney disease."
Genetic Disorders • Nephrology • Renal Disease • COL4A5 • PIK3R1
|
|
Courtney Willey; Susan Marie Sheehan; Peter C. Reifsnyder; Samantha Spellacy; Ron Korstanje
|